Erenumab effectiveness and safety: comparison of real-life data and clinical trial results
Background. Erenumab was the first preventive medication targeted to the pathogenesis of migraine to reach Lithuanian market. Previously, evidence of the safety and efficacy of erenumab was supported only by clinical study results, but more recently, real-life data started to appear. The aim of thi...
Saved in:
| Main Authors: | Austėja Dapkutė, K. Ryliškienė |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Vilnius University Press
2021-12-01
|
| Series: | Neurologijos seminarai |
| Subjects: | |
| Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/27594 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study
by: Charly Gaul, et al.
Published: (2024-10-01) -
Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis
by: Mohamed E. Haseeb, et al.
Published: (2025-03-01) -
A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland
by: Caroline S. Casey, et al.
Published: (2025-04-01) -
Influence of Constipation in the Behavior of Circulating Alpha- and Beta-CGRP Levels in Chronic/High-Frequency Migraine Patients After CGRP Monoclonal Antibodies
by: Gabriel Gárate, et al.
Published: (2025-05-01) -
Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)